Isracann Biosciences Valuation
Is ISCN.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ISCN.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ISCN.F's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ISCN.F's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ISCN.F?
Other financial metrics that can be useful for relative valuation.
What is ISCN.F's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CA$237.90 |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ISCN.F's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 0.003x | ||
RVLP.Q RVL Pharmaceuticals | 0.000007x | n/a | US$111.0 |
CLVR Clever Leaves Holdings | 0.00002x | n/a | US$526.0 |
HENC Hero Technologies | 0.01x | n/a | US$563.0 |
INLB Item 9 Labs | 0.00001x | n/a | US$701.0 |
ISCN.F Isracann Biosciences | n/a | n/a | US$176.0 |
Price-To-Book vs Peers: Insufficient data to calculate ISCN.F's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Earnings Ratio vs Industry
How does ISCN.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: Insufficient data to calculate ISCN.F's Price-To-Book Ratio vs. industry for valuation analysis.
Price to Book Ratio vs Fair Ratio
What is ISCN.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | n/a |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate ISCN.F's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.